- About Us
- Phase I
- Phase II
- Data Services
- Core Laboratories
- Media Center
The FDA has approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.
Status: Recruiting, Condition Summary: Hot Flashes; Menopause; Vasomotor Disturbance; Sleep
Almac, a contract development and manufacturing organization, has been named national champion in the UKTI Award for Innovation category in this year’s European Business Awards—a competition supported by businesses leaders, academics, media and political representatives across Europe.
The Leukemia & Lymphoma Society (LLS) has appointed Louis J. DeGennaro, Ph.D., president and CEO, effective immediately.
SRI International, a California-based independent nonprofit research institute, and Nobelpharma, a Japanese pharmaceutical company, have entered into a licensing agreement to test SR16234, an SRI drug candidate that may be effective in treating endometriosis. SR16234 is a member of a class of drugs known as selective estrogen receptor modulators (SERMs) that regulate the effects of the hormone estrogen.
Medidata, a NewYork-based global provider of cloud-based solutions for clinical research in life sciences, and global CRO Icon have formed a joint initiative designed to bring new efficiencies to the administration of electronic patient-reported outcomes (ePROs) in clinical trials. The new offering provides sponsors with an ePRO solution that reduces costs, saves time and enhances patient engagement.
MabVax Therapeutics Holdings, a San Diego-based clinical stage oncology drug development company, has entered into agreements with New York City’s Memorial Sloan-Kettering Cancer Center (MSKCC) and Seattle-based Juno Therapeutics for the development of novel therapeutic products using antibody targeting sequences derived from the fully-human antibodies discovered using the company's internally developed antibody discovery platform.
PharmAthene, an Annapolis, Md.-based biodefense company developing medical countermeasures against biological and chemical threats, has announced the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has awarded the company a contract, valued at up to $28.1 million if all contract options are exercised, for the development of a next-generation anthrax vaccine based on the company's proprietary rPA anthrax vaccine technology platform.
NICE will ask for access to clinical trial data from European regulatory authorities if pharmaceutical companies fail to supply all relevant data. The move follows calls for increasing transparency from pharma companies and comes after Roche was criticized for its handling of data for the pandemic flu drug Tamiflu.
The market for psoriatic arthritis (PsA) therapies will grow nearly 66%, increasing to $3.7 billion in 2023, due to the continued uptake of premium-price biologics and novel therapies expected to launch during the 2013 to 2023 forecast period, according to Burlington, Mass.-based Decision Resources Group.
Seattle Genetics, a biotech company focused on development and commercialization of innovative antibody-based therapies for cancer, and Genmab, a Denmark-based international biotech company specializing in differentiated human antibody therapeutics for cancer, have entered into an additional antibody-drug conjugate (ADC) collaboration.
Status: Recruiting, Condition Summary: Alzheimer's Disease
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue
Status: Active, not recruiting, Condition Summary: Leukemia; CLL
The list has been updated through August 2014.
PMG Research (PMG), an integrated network of clinical research facilities in the southeastern U.S., has established its 11th clinical research site, PMG Research of Rocky Mount. PMG Research has assumed ownership and operation of the clinical research department at Boice-Willis Clinic in Rocky Mount, N.C., further expanding PMG’s presence in eastern North Carolina. This new site enhances PMG’s access to an additional 130,000 patients.
Information and specialized care can help patients become more engaged in their own treatment and in the Parkinson's disease (PD) community, according to a recent online survey of more than 1,500 PD patients, caregivers and physicians conducted by Harris Poll on behalf of the Michael J. Fox Foundation and AbbVie.
The U.S. interventional oncology device market will see strong growth, reaching a value of $760 million by 2023, according to Decision Resources Group. Rising cancer incidence rates, combined with the ineffectiveness of chemotherapy and demand for less invasive procedures, will support interventional oncology device uptake.
Almac, a contract development and manufacturing organization headquartered in Craigavon, Northern Ireland, has released a new clinical Supply Chain Management (SCM) service as a response to growth in demand for biologics and global trials.
NeuroVive Pharmaceutical, a Swedish mitochondrial medicine company, has signed an exclusive global out-licensing agreement with the Pennsylvania-based OnCore BioPharma for the development and commercialization of NeuroVive’s drug candidate NVP018 for oral treatment of chronic hepatitis B virus (HBV) infection. The agreement could give NeuroVive a total of $150 million in conditional milestone payments, plus royalties on future drug sales.
Livongo Health, a California-based consumer digital health company, has launched with a vision to empower people with chronic conditions to live better through the combined power of technology, real-time personalized information and support from a chosen care team.